HSP70L1-mediated intracellular priming of dendritic cell vaccination induces more potent CTL response against cancer
/in Dendritic Cells, International Publications /von 2016-06-27 / Cell. Mol. Immunol. 2018 02;15(2):135-145Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
/in Checkpoint-Inhibitors, International Publications /von 2016-06-21 / Immunity 2016 06;44(6):1255-69Dendritic cell vaccination in melanoma patients: From promising results to future perspectives
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2016-06-20 / Hum Vaccin Immunother 2016 10;12(10):2523-2528Anti-tumor efficacy of the Runx2-dendritic cell vaccine in triple-negative breast cancer in vitro.
/in Breast Cancer, Dendritic Cells, International Publications /von 2016-06-17 / J Clin Oncol 36, 2018 (suppl; abstr e24000)Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2016-06-17 / Oncoimmunology 2016 Aug;5(8):e1201625Thermosensitive liposomal cisplatin in combination with local hyperthermia results in tumor growth delay and changes in tumor microenvironment in xenograft models of lung carcinoma
/in Hyperthermia, International Publications, NSCLC /von 2016-06-16 / J Drug Target 2016 11;24(9):865-877Comparison of biological effects of modulated electro-hyperthermia and conventional heat treatment in human lymphoma U937 cells
/in Hyperthermia, International Publications, Malignant Lymphoma /von 2016-06-13 / Cell Death Discov 2016;2:16039Fachbeitrag von Prof. Schirrmacher zur Effizienz und Effektivität der Krebsbehandlung, Wiener klinisches Magazin
/in IOZK In der Presse, IOZK Veröffentlichungen /von IOZKProgress of dendritic cell-based cancer vaccines for patients with hematological malignancies
/in Acute Leukemia, Chronic Leukemia, Dendritic Cells, International Publications /von 2016-06-09 / Expert Opin Biol Ther 2016 09;16(9):1113-23
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution